Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis

New England Journal of Medicine

Volumn 373, Issue 26, 2015, Pages 2534-2548

  Baeten, Dominique ^a   Sieper, Joachim ^b   Braun, Jürgen ^c   Baraliakos, Xenofon ^c   Dougados, Maxime ^d   Emery, Paul ^e   Deodhar, Atul ^f   Porter, Brian ^g   Martin, Ruvie ^g   Andersson, Mats ^g   Mpofu, Shephard ^g   Richards, Hanno B ^g  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c RHEUMAZENTRUM RUHRGEBIET   (Germany)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SECUKINUMAB; IL17A PROTEIN, HUMAN; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY; CANDIDIASIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; SPONDYLITIS, ANKYLOSING;

ADULT; ANTIBODIES, MONOCLONAL; CANDIDIASIS; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; NEUTROPENIA; SPONDYLITIS, ANKYLOSING;

EID: 84952025973     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1505066     Document Type: Article

References (37)

1. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011; 377: 2127-37.
2. Jang JH, Ward MM, Rucker AN, et al. Ankylosing spondylitis: patterns of radiographic involvement - a re-examination of accepted principles in a cohort of 769 patients. Radiology 2011; 258: 192-8.
3. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369: 1379-90.
4. Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ 2012; 15: 1054-63.
5. Braun J, van den Berg R, Baraliakos X, et al. 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904.
6. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6.
7. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91.
8. van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009; 68: 922-9.
9. Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382: 1705-13.
10. Baraliakos X, Landewé R, Hermann KG, et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005; 64: 730-4.
11. De Lay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009; 60: 2633-43.
12. Glatigny S, Fert I, Blaton MA, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum 2012; 64: 110-20.
13. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8-entheseal resident T cells. Nat Med 2012; 18: 1069-76.
14. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 1647-56.
15. Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 2011; 186: 2672-80.
16. Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012; 64: 1420-9.
17. Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011; 13: R95.
18. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012; 64: 99-109.
19. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med 2014; 371: 326-38.
20. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
21. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
22. Klein U, Liang E, Vogel B, Kolbinger F, Bruin G, Lloyd P. Immunogenicity of the anti-IL17A antibody secukinumab in healthy patients and patients. J Invest Dermatol 2013; 133: Suppl 1: S172.abstract.
23. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of Spondylo Arthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68: Suppl 2: ii1-ii44.
24. Ware JE, Kosinski M, Dewey JE. How to score Version Two of the SF-36 Health Survey. Lincoln, RI: Quality Metric, 2000.
25. Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003; 62: 20-6.
26. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 June 2010 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference -5x7.pdf).
27. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402-12.
28. Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009; 28: 586-604.
29. Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 2014; 74: 1051-7.
30. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014; 73: 95-100.
31. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011; 70: 1108-10.
32. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005; 64: 296-8.
33. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-fourweek clinical trial. Arthritis Rheum 2010; 62: 1290-7.
34. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
35. Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014; 73: 39-47.
36. Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013; 72: 863-9.
37. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.